F014 HIV and STIs: Hot Topics
DESCRIPTION
Sexually transmitted infection rates have been rapidly increasing in the post-pandemic world. Patients frequently present to their dermatologist for evaluation and management of their STIs. The nature of infectious diseases is that the epidemiology and treatment options are always changing. This session will update the clinicians with the latest trends in STIs like HIV, HSV, Mpox and syphilis and guide them in appropriate lab testing and best and newest treatment options for their patients.
LEARNING OBJECTIVES
Recognize the changing epidemiology of sexually transmitted infections that affect the skin.
Order appropriate lab evaluations for patients with STIs.
Select the most appropriate treatment for patients with STIs that affect the skin.
SCHEDULE
1:00 PM
Herpes at the Crossroads: From Common Infection to Drug Resistance
Kieron S. Leslie, MBBS
1:30 PM
Biologic and Targeted Therapies for Inflammatory Skin Disease in People with HIV
Philip R. Doiron, MD, FAAD
2:00 PM
Syphilis: What’s New with an Old Disease?
Erin H. Amerson, MD, FAAD
2:30 PM
Sexually Transmitted Infections and Prevention in Dermatology Practice: What's New and What's Next
Jason Zucker
DIRECTOR
Kieron S. Leslie, MBBS
SPEAKERS
Erin H. Amerson, MD, FAAD
Philip R. Doiron, MD, FAAD
Jason Zucker
DISCLOSURES
Erin H. Amerson, MD, FAAD
No financial relationships exist with ineligible companies.
Philip R. Doiron, MD, FAAD
AbbVie – Advisory Board(Honoraria); Amgen – Advisory Board(Honoraria); Eli Lilly – Advisory Board(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Kieron S. Leslie, MBBS
No financial relationships exist with ineligible companies.
Jason Zucker
No financial relationships exist with ineligible companies.